A Phase II Study Using ACP-196 in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Anti-Tumor Response

Trial Profile

A Phase II Study Using ACP-196 in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Anti-Tumor Response

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Acalabrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 06 Nov 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017, as reported by ClinicalTrials.gov.
    • 20 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top